Unichem Laboratories Limited announced that it has received ANDA approval for its Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Ranexa®? (ranolazine extended-release tablets) 500 mg and 1,000 mg, of Gilead Sciences Inc. Ranolazine Extended-Release Tablets, 500 mg, and 1,000 mg are indicated for the treatment of chronic angina. The product will be commercialized from Unichem's Goa Plant.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
541.6 INR | -1.70% | -1.21% | +33.09% |
1st Jan change | Capi. | |
---|---|---|
+33.09% | 465M | |
+40.49% | 731B | |
+31.34% | 586B | |
-7.29% | 348B | |
+16.77% | 319B | |
+0.29% | 273B | |
+13.47% | 235B | |
-6.63% | 203B | |
+7.49% | 202B | |
+3.91% | 159B |
- Stock Market
- Equities
- 506690 Stock
- News Unichem Laboratories Limited
- Unichem Laboratories Limited Receives ANDA Approval for its Ranolazine Extended-Release Tablets, 500 Mg and 1,000 Mg from the United States Food and Drug Administration